Biomarker Study for Combined nivolumab and ipilimumab in Fecal microbiota metabolites of Advanced malignant melanoma

Biomarker Study for Combined nivolumab and ipilimumab in Fecal microbiota metabolites of Advanced malignant melanoma - SCFA study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039666

Enrollment

Registered

2020-06-01

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant melanoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically diagnosed as malignant melanoma. 2) Clinically and imagingly diagnosed as unresectable malignant melanoma. However, choroidal melanoma is excluded. 3) Over 20 years old. 4) Nivolumab + ipilimumab combination therapy is planned for future treatment. 5) Having a measurable lesion. 6) No prior treatment with ipilimumab. 7) The patient has given written consent to participate in the study.

Exclusion criteria

Exclusion criteria: Patients who are considered inappropriate for the investigator to participate in the study are excluded.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactMotoo Nomura

Kyoto University Hospital Therapeutic oncology

mnomura@kuhp.kyoto-u.ac.jp075-751-3518

Outcome results